RemeGen’s Disitamab Vedotin on Track for Breakthrough Designation in Muscle Invasive Bladder Cancer
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that its antibody-drug...
Guangzhou Boosts Innovative Drug Development with New HSA Initiatives
The Healthcare Security Administration (HSA) bureau in Guangzhou’s province has issued a notification outlining measures...
Gan & Lee Pharmaceuticals Gains Marketing Approval for Insulin Glargine in Mexico
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...
China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition
Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with...
Keymed Biosciences’ Stapokibart Earns Priority Review for Chronic Sinusitis Treatment in China
Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced that its...
Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive...
Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab
Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking...
Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals
Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a...
MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...
Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03
Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and...
Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement
China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement...
China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...
Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans...
Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...
Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...
NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment
NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...
C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain
C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a...
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...
Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in...
Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...